Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial

(2012) P. Nair et al.   CLINICAL AND EXPERIMENTAL ALLERGY

SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans

(2011) Aili L. Lazaar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor

(2011) R. Virtala et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Severe asthma: Advances in current management and future therapy

(2011) Peter J. Barnes   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

A Self-Propagating Matrix Metalloprotease-9 (MMP-9) Dependent Cycle of Chronic Neutrophilic Inflammation

(2011) Xin Xu et al.   PLoS One

Neutrophils in chronic inflammatory airway diseases: can we target them and how?

(2010) Y. Gernez et al.   EUROPEAN RESPIRATORY JOURNAL

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects

(2009) O. Holz et al.   EUROPEAN RESPIRATORY JOURNAL

New drugs for exacerbations of chronic obstructive pulmonary disease

(2009) Trevor T Hansel et al.   LANCET

CXCR2 antagonists for the treatment of pulmonary disease

(2008) R.W. Chapman et al.   PHARMACOLOGY & THERAPEUTICS

Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputum

(2008) K J Mackerness et al.   THORAX